1. Introduction {#s0005}
===============

Magnetic resonance diffusion weighted imaging (DWI) remains the best neuroimaging technique to detect acute ischemia, above all since the new tissular definition of transient ischemic attack (TIA) has become essential in the evaluation of TIA patients ([@bb0035]). According to a recent meta-analysis, despite transient clinical symptoms, one out of three patients with definite TIA has an acute DWI lesion ([@bb0030]). Moreover, DWI has been shown to be an important predictor of early stroke recurrence ([@bb0105]) and it has been proposed to add to clinical prognostic scales like ABCD2I ([@bb0040]) and ABCD3I ([@bb0095]). Furthermore, not only the presence but also the patterns of DWI are important both for the etiological classification and for patient prognosis ([@bb0110]). However, despite the increased availability of magnetic resonance imaging (MRI) not all TIA patients undergo DWI. Therefore, the discovery of a plasmatic biomarker related to neuroimaging findings is of enormous interest.

The use of metabolomics on TIA patients has started a new era in biomarker discovering for clinical purpose ([@bb0060]). Metabolomics allows the study of the complete set of low-molecular-weight intermediates (metabolites), which vary according to the pathologic state of the cell, tissue, organ, or organism and are context-dependent ([@bb0055], [@bb0085]).

The aim of the present study was to perform a metabolomic analysis to find new biomarkers associated with the presence of acute DWI lesion and the volume and patterns of these lesions. As previously ([@bb0060]), results were validated in an independent cohort.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

This study was approved by the ethics committee of the Arnau de Vilanova University Hospital. The main methodology has been previously described ([@bb0060]). We prospectively recruited two independent cohorts of consecutive TIA patients who were attended to by a neurologist during the first 24 h after the onset of symptoms. Both cohorts shared the same methodology but were recruited at different times ([Fig. 1](#f0005){ref-type="fig"}). We excluded 12 patients with contraindications to MRI from the original study. We therefore analyzed 129 patients from cohort 1 and 152 patients from cohort 2. TIA was defined according to the classical definition as acute onset of focal cerebral or monocular symptoms lasting \< 24 h and thought to be attributable to a brain ischemia ([@bb0015]). In order to avoid ethnic differences in the observed metabolomic profiles, all the patients included were Caucasian in origin. Patients were classified etiologically according to the Trial of ORG 10172 (TOAST) ([@bb0005]). Undetermined territory included patients without higher brain function disturbance such us aphasia, hemianopsia, neglect, or vertebrobasilar symptoms. Vertebrobasilar TIA was characterized by the following symptoms: bilateral or shifting motor or sensory dysfunction, complete or partial loss of vision in homonymous fields, dizziness, vertigo, or any combination thereof ([@bb0110]).

2.2. Neuroimaging Protocol {#s0020}
--------------------------

A MRI was acquired using a 1.5-T whole-body system with a 24-mT/m gradient strength, 300 ms rise time, and an echo-planar--capable receiver equipped with a gradient overdrive (Philips Intera 1.5 T, MRI scanner). The images obtained included axial T2-weighted turbo spin-echo (TR/TE: 4800/120), T1-weighted spin-echo (TR/TE: 540/15), axial turbo fluid-attenuated inversion recovery (TR/TI/TE: 8000/2200/120), and echo-planar diffusion images (TR/TE: 3900/95). The field of view was 230 mm and the matrix was 256 × 256 in all sequences. The DWI were obtained with a single-shot spin-echo echo-planar pulse sequence with diffusion gradient b values of 1000 s/mm2 along orthogonal axes over 20 axial sections, using 6 mm thick sections, and an interslice gap of 1 mm. Tissue abnormality (positive DWI) was defined as areas of high signal intensity on isotropic DWI reflecting an acute ischemic lesion. Patterns of DWI were determined according to a previous definition ([@bb0110]): DWI normality, scattered pearls in one arterial territory (SPOT), multiple vascular territories, a single cortical lesion in one vascular territory and a subcortical pattern. Two Neuroradiologists blinded to clinical features established the presence and patterns of DWI abnormalities. The interobserver agreement (kappa value) is 1.0 for identifying positive DWI and 0.98 for identifying DWI patterns. Furthermore, OsiriX V.4.0 imaging software ([@bb0125]) was used to calculate the total volume of DWI abnormality. We manually outlined the respective abnormalities using the OsiriX closed polygon tool, thereby creating a region of interest (ROI). ROIs in between the segmented slices were interpolated automatically. The resulting DWI abnormality volume was then determined.

2.3. Metabolomic Analysis {#s0025}
-------------------------

For non-targeted metabolomic analysis, plasma samples were obtained in the morning in order to avoid diurnal variations and metabolites were extracted with methanol according to previously described methods ([@bb0160]). Briefly stated, 90 μl of cold methanol (containing phenylalanine-C13 as an internal standard) were added to 30 μl of plasma, incubated for one hour at − 20 °C and centrifuged for three minutes at 12,000*g*. The supernatant was recovered, evaporated using a Speed Vac (Thermo Fisher Scientific, Barcelona, Spain) and resuspended in water containing 0.4% acetic acid/methanol (50/50).

We used an ultra-high pressure liquid chromatography (UHPLC) scheme with an Agilent 1290 LC system coupled to an electrospray-ionization quadruple time of flight mass spectrometer (Q-TOF) 6520 instrument (Agilent Technologies, Barcelona, Spain). A column with a particle size of 1.8 μm was employed. The preliminary identification of differential metabolites was performed using the PCDL database from Agilent (Agilent Technologies, Barcelona, Spain), which uses retention times, exact mass and isotope distribution in an standardized chromatographic system as an orthogonal searchable parameter to complement accurate mass data (AMRT approach) according to previously published works ([@bb0130]). The version of the PCDL database used had retention times and accurate mass data for 679 compounds.

2.4. Statistical Analysis {#s0030}
-------------------------

Statistics calculations were performed using the SPSS software version 20 (SPSS, Chicago, IL) or the Stata 11 statistics package (StataCorp, College Station, TX). Normal distribution of the variables was checked by the Kolmogorov-Smirnoff test. Partial least discriminate analysis (PLS-DA) was performed using Mass Molecular Profiler software (Agilent Technologies, Barcelona, Spain). Briefly stated, the number of components chosen for PLS-DA was 4, and data were scaled using an auto scaling algorithm. Validation of the model was achieved with a N-fold validation type with 3 folds and 10 repeats as validation parameters. In all cases, significance was considered for p \< 0.05.

Statistical significance for intergroup differences was assessed using the Χ^2^ test for categorical variables and the Student\'s *t*-test, ANOVA test and Mann-Whitney *U* test for continuous variables. Univariate analyses were performed to detect variables associated with the presence of positive DWI and DWI patterns. Assuming that the ischemia volume determined on DWI could be considered to constitute a continuous variable, we tested whether any circulating metabolite could be correlated with it. Receiver operating characteristic (ROC) curves for metabolomic data were performed using the ROCCET platform. ROC curves were plotted to predict the presence of positive DWI and DWI patterns.

3. Results {#s0035}
==========

As we have published previously, we did not find any statistically significant differences between the two cohorts based on vascular risk factors, clinical characteristics and neuroimaging data ([@bb0065]). We observed DWI abnormalities in 115 (40.9%) patients. Moreover, SPOT pattern, present in 41 (35.7%) patients, was the most frequent pattern ([Table 1](#t0005){ref-type="table"}). Clinical features, vascular risk factors and etiology varied significantly among the different DWI patterns ([Table 2](#t0010){ref-type="table"}). Patients who had DWI abnormalities in multiple territories were older than patients with other patterns. Motor weakness was more frequent among subcortical lesion and multiple territories pattern. LAA was the most frequent etiology among SPOT. Moreover, SPOT and multiple territories pattern had higher volumes of DWI lesion. The median acute ischemic lesion volume was 0.33 (0.15--1.90) cm^3^.

3.1. Metabolomics and Positive DWI {#s0040}
----------------------------------

Following metabolomic analyses of the discovery and validation cohorts, a distinctive pattern of metabolites was found. As shown in the heatmap ([Fig. 2](#f0010){ref-type="fig"}A), positive DWI exhibited a differential metabolomic profile in the discovery cohort. For PLSDA modeling, a three-component model with a high degree of accuracy (0.62, R2 = 0.85) was obtained in the discovery cohort ([Fig. 2](#f0010){ref-type="fig"}A). Similarly, the PLSDA model in the validation cohort also reached a high degree of accuracy (0.64, R2 = 0.96, [Fig. 2](#f0010){ref-type="fig"}B). In addition to the separation offered by the PLSDA plot, whose axis showed the integration of multiple compounds, we explored the capacity of individual metabolites to explain separation between DWI and non-DWI groups. The results ([Fig. S1](#ec0020){ref-type="supplementary-material"}) revealed that several molecules could differentiate these groups, with receiving operating characteristic curves consistent in both cohorts. Univariate statistics showed that a total of 87 molecular features in the discovery cohort were significantly different between positive DWI and normal DWI patients (Student\'s *t*-test, p values between 6.98 E − 5 and 0.05, supplemental dataset 1). After applying the same approach to the validation cohort, 379 molecular features showed significant differences between these two groups (Student\'s *t*-test, p values between 2.34 E − 5 and 0.05, supplemental dataset 1). When searching for common differential molecular features shared by these two cohorts, 11 molecular features were found ([Table 3](#t0015){ref-type="table"}). When we applied a database search using the PCDL software (integrating exact masses, isotope distribution and retention time identity with an identical LC/MS system) it was possible to propose several identities ([Table 3](#t0015){ref-type="table"}), including creatinine, threoninyl-threonine, *N*-acetyl-glucosamine, lysophosphatidic acid (LPA) and a cholesterol-related molecule. Most differential compounds showed ROC areas (data not shown) between 0.6 and 0.65, demonstrating that these molecules could serve as potential biomarkers for acute ischemic lesions on DWI.

3.2. Metabolomics and Acute Ischemic Lesion Volume {#s0045}
--------------------------------------------------

In the discovery cohort, 43 molecules showed a significant correlation with acute ischemic lesion volume (Pearson correlation test, p values between 3.12 E − 07 and 0.05, Supplementary dataset 2). In the validation cohort 211 molecules showed this feature (Pearson correlation test, p values between 1.31 E − 10 and 0.05, supplementary data set 2). After searching for common molecules, a total of 7 different molecules were found including lysophosphatidylcholine, hypoxanthine/threonate, and leucine ([Table 4](#t0020){ref-type="table"}). Globally, these molecules showed a significant direct relationship with ischemia volume.

3.3. Metabolomics and DWI Patterns {#s0050}
----------------------------------

The results for the discovery cohort suggest specific metabolomic profiles that cluster patients according to their DWI pattern. Subcortical pattern patients were therefore clearly different from those with isolated cortical lesions and those with normal DWI according to a PLSDA model with a moderate degree of accuracy (two-component model 0.503, R2 0.63, [Fig. 3](#f0015){ref-type="fig"}A). This was confirmed by the analysis in the confirmation cohort, where accuracy increased (two-component model 0.58, R2 0.92, [Fig. 3](#f0015){ref-type="fig"}B). This supported the notion that, according to the metabolomic profiles, the subcortical DWI pattern could be clearly differed from other patterns, such us isolated cortical lesions and DWI negative patients. A random forest classification scheme confirmed these findings, with subcortical patterns being classified with lower margin of error (\< 0.05) in both cohorts.

In the case of univariate measurements, in the first cohort a total of 81 molecules were seen to be significantly different from these patterns (p values ranging between 2E − 04 and 0.05, Supplemental dataset 3). In the confirmation cohort, 285 molecules differed across the DWI pattern (p values between 5.94E − 11 and 0.05, Supplemental dataset 3). Confirming the existence of potential biomarkers for the DWI pattern, 8 molecules were found to be common between these two cohorts ([Table 5](#t0025){ref-type="table"}). These comprised lysophospholipids, as well as creatinine and other unknown metabolites.

4. Discussion {#s0055}
=============

To the best of our knowledge, this is the first time that a metabolomics approach has revealed potential biomarkers related to neuroimaging findings after TIA. Previous data from different groups related metabolomics data with neuroimaging in the context of bipolar disorder ([@bb0090]), multiple sclerosis ([@bb0150]), dementia such as Alzheimer\'s disease ([@bb0075]), schizophrenia ([@bb0155]), Parkinson disease ([@bb0120]) and even pediatric cerebral infections ([@bb0100]). We found a specific metabolomic profile related to acute ischemic lesions, volume and specific acute ischemic patterns. In a previous report, [@bb0025], using magnetic resonance spectroscopy, discovered in ischemic stroke patients with posttreatment hyperperfusion signs of increased glutamate, *N*-acetylaspartate and lactate. These changes were related to increased metabolism and potentially enhanced ulterior neuroplasticity. In our case, positive DWI was linked to changes in several other metabolites, such as creatinine, *N*-acetyl-glucosaminylamine and LPA. Interestingly, *N*-acetyl-glucosaminylamine, that is structurally related to *N*-acetyl-glucosamine, and other similar molecules are modulators of immune response ([@bb0140]) when expressed at the endothelial membrane. Assuming the important role of microglia and activated neutrophils in brain ischemia response ([@bb0010]), the present findings could be in line with changes in expression and cleavage of glycoprotein components. It should be noted that, one of the potential markers for DWI positivity was a low level of LPA. These molecules, and their signaling through their cognate receptor LPA1, have been implicated in the generation of ischemia-related neuropathic pain ([@bb0045]). Moreover, some molecules from this family are also considered angiogenic factors ([@bb0115], [@bb0020]). Therefore, diminished levels may be associated with a lower capacity to withstand hypoxia-induced apoptosis ([@bb0080]). Interestingly, other researchers have found increased LPA in plasma from patients with vascular cerebral ischemia ([@bb0070]). In this context, both activated platelets and atheroma plaque are known sources of LPA ([@bb0050]). The fact that LPA is a platelet activator and thrombotic agent reveals the potential involvement of these molecules in cerebral changes linked to hypoxia. In order to explain whether the decreased LPA observed in our DWI positive patients is a protective trait (in light of its thrombogenic role) or a negative feature (based on the antiapoptotic properties), it should be taken into account that we have specifically found an increase in LPA (O-20:0). Furthermore, the structure-function relationships for LPAs are strongly dependent on the side chain ([@bb0050]).

As in our previous work ([@bb0065]), specific patterns of LysoPC were again relevant. LysoPC (22:6) and LysoPC (20:4), that were previously related to LAA and stroke recurrence respectively, were now associated with lesion volume. Furthermore, LysoPC (16:0), that was low in those TIA patients who suffered a subsequent stroke, was now related to SPOT and cortical patterns. All these associations made sense because SPOT and cortical patterns which are overrepresented in LAA patients ([@bb0110]) had the biggest lesion volume.

Our work shows some inherent limitations. The fact that the patients were heterogeneous in fasting time, as well as differences in gender, etiology, pharmacological treatment or age, to name a few, could hinder some potential biomarkers. Moreover, plasma metabolites levels could be influenced by many factors such as diet, medications, age and clinical variables ([@bb0085]). However, the use of two cohorts allows overcoming these potential limitations, increasing the robustness of the resulting data ([@bb0060], [@bb0135]). A further limitation of the present work is the fact that many molecules where not identified, although it is a common circumstance for these kind of analyses ([@bb0145]). However, the use of orthogonal approaches, such as the use of retention time in standardized chromatographic systems, exact mass and isotope pattern, could help to overcome this limitation, leading to the formulation of potential biomarkers ([@bb0130]). Additionally, there is an important step left to be done in order to implement our results in the everyday clinical practice. We have to recognize that metabolomic analysis is too expensive and requires extensive temporal and personal resources. So once potential biomarkers are identified, economic and fast techniques, amenable to most clinical laboratories, need to be developed to detect them. Finally, we included only TIA patients even we knew that the diagnosis of transient ischemia could sometimes be problematic as many conditions mimic this situation. Further research should be done in big tissue-defined ischemia cohorts to confirm our results.

Globally, our data support the existence of metabolic patterns associated with neuroimaging features after transient brain ischemia that could allow the development of serum biomarkers related to acute ischemic lesions and specific acute ischemic patterns.

The following are the supplementary data related to this article.Molecular features in the discovery cohort that were significantly different between positive DWI and normal DWI patients.Supplemental dataset 1Molecules that showed a significant correlation with acute ischemic lesion volume in the discovery cohort.Supplemental dataset 2Molecules that were significantly different between DWI patterns in the discovery cohort.Supplemental dataset 3Fig. S1Individual molecules identified by metabolomic analyses contributing to separation between DWI and non-DWI individuals. Receiving operating characteristics curves are shown for those molecules that, before normalization and autoscaling for multivariate statistics, showed higher areas under the curve.Fig. S1
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###### 

Risk factors, clinical characteristics and neuroimaging data of both cohorts.

Table 1.

  Variable                             Cohort 1 (n = 129)   Cohort 2 (n = 152)   Total (n = 281)     p
  ------------------------------------ -------------------- -------------------- ------------------- -------
  Vascular risk factors                                                                              
   Age, mean (SD)                      71.1 (10.4)          71.8 (11.2)          71.5 (10.8)         0.623
   Male                                83 (64.3)            91 (59.9)            174 (61.9)          0.442
   Previous stroke                     28 (21.7)            34 (22.5)            62 (22.1)           0.894
   Hypertension                        89 (69.0)            102 (67.1)           191 (68.0)          0.735
   Coronary disease                    17 (13.2)            20 (13.2)            37 (13.2)           0.996
   Diabetes mellitus                   40 (31.0)            44 (28.9)            84 (29.9)           0.707
   Smoking                             18 (14.0)            18 (11.8)            36 (12.8)           0.598
   Hypercholesterolemia                49 (38.0)            59 (38.8)            108 (38.4)          0.886
   Previous atrial fibrillation        17 (13.2)            15 (9.9)             32 (11.4)           0.384
  Basal treatments                                                                                   
   Aspirin                             30 (23.3)            36 (23.8)            66 (23.6)           0.908
   Clopidogrel                         8 (6.2)              17 (11.3)            25 (8.9)            0.139
   Anticoagulation                     19 (14.7)            10 (6.6)             29 (10.4)           0.026
   Statins                             43 (33.6)            46 (30.5)            89 (31.9)           0.576
   Renin-angiotensin system blockers   64 (49.6)            71 (47.7)            135 (48.6)          0.744
  Clinical features                                                                                  
   Duration                                                                                          
    \< 10′                             12 (9.3)             16 (10.5)            28 (10.0)           0.925
   10--59′                             49 (38.0)            56 (36.8)            105 (37.4)          
   1 h                                 68 (52.7)            80 (52.6)            148 (52.7)          
   Cluster TIA                         35 (27.1)            33 (21.7)            68 (24.2)           0.290
   Weakness                            69 (53.5)            78 (51.3)            147 (52.3)          0.716
   Isolated sensory symptoms           12 (9.3)             13 (8.6)             25 (8.9)            0.826
   Speech impairment                   76 (58.9)            94 (62.3)            170 (60.7)          0.569
   Vertebrobasilar                     10 (7.8)             12 (7.9)             22 (7.9)            0.952
   ABCD2, median (IQR)                 5.2 (4.0--6.0)       5.1 (4.0--6.0)       5.1 (4.0--6.0)      0.753
  Etiological subtypes                                                                               
   Large artery atherosclerosis        32 (24.8)            29 (19.2)            61 (21.8)           0.509
   Cardioembolism                      23 (17.8)            35 (23.2)            58 (20.7)           
   Small-vessel disease                28 (21.7)            29 (19.2)            57 (20.4)           
   Undetermined cause                  46 (35.7)            58 (38.4)            104 (37.1)          
  Neuroimaging features                                                                              
   DWI abnormality                     59 (45.7)            56 (36.8)            115 (40.9)          0.145
   Scattered pearls on one territory   18 (14.0)            23 (15.4)            41 (14.7)           0.485
   Multiple territories                4 (3.1)              3 (2.0)              7 (2.5)             
   Single cortical lesion              18 (14.0)            16 (10.7)            34 (12.2)           
   Subcortical lesion                  19 (14.7)            14 (9.4)             33 (11.9)           
   DWI normality                       70 (54.3)            93 (62.4)            163 (58.6)          
   DWI volume, mean (SD)               0.36 (0.15--1.91)    0.33 (0.15--2.45)    0.33 (0.15--1.90)   0.987

Percentages are shown in parentheses as appropriate.

DWI, diffusion-weighted images; TIA, transient ischaemic attacks; SD, standard deviation; IQR, interquartile range.

###### 

Risk factors and clinical features by DWI patterns.

Table 2.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                        All cases\          DWI normality\   Scattered pearls one territory\   Multiple territories\   Single cortical lesion\   Subcortical lesion\   p
                                  (n = 281)           (n = 166)        (n = 41)                          (n = 7)                 (n = 34)                  (n = 33)              
  ------------------------------- ------------------- ---------------- --------------------------------- ----------------------- ------------------------- --------------------- ----------
  Vascular risk factors                                                                                                                                                          

   Age, mean (SD)                 71.5 (10.8)         73.4 (9.9)       69.2 (11.3)                       74.1 (5.5)              68.8 (13.8)               67.2 (10.2)           0.005

   Male                           174 (61.9)          95 (57.2)        32 (78.0)                         5 (71.4)                20 (58.8)                 22 (66.7)             0.165

   Hypertension                   191 (68.0)          118 (71.1)       27 (65.9)                         4 (57.1)                20 (58.8)                 22 (66.7)             0.687

   Previous stroke                62 (22.1)           42 (25.3)        8 (19.5)                          2 (28.6)                7 (20.6)                  3 (9.1)               0.340

   Diabetes mellitus              84 (29.9)           58 (34.9)        7 (17.1)                          1 (14.3)                9 (26.5)                  9 (27.3)              0.175

   Coronary disease               37 (13.2)           23 (13.9)        6 (14.6)                          1 (14.3)                6 (17.6)                  1 (3.0)               0.448

   Smoking                        36 (12.8)           13 (7.8)         8 (19.5)                          0 (0)                   7 (20.6)                  8 (24.2)              0.020

   Hypercholesterolemia           108 (38.4)          64 (38.6)        17 (41.5)                         5 (71.4)                18 (52.9)                 4 (12.1)              0.003

   Previous atrial fibrillation   32 (11.4)           20 (12.3)        9 (22.0)                          1 (14.3)                1 (2.9)                   1 (3.0)               0.054

  Clinical features                                                                                                                                                              

   Cluster TIA                    68 (24.2)           31 (19.0)        13 (31.7)                         3 (42.9)                9 (26.5)                  10 (30.3)             0.216

   Speech impairment              170 (60.7)          103 (63.6)       20(48.8)                          3 (42.9)                19 (55.9)                 22 (66.7)             0.317

   Motor weakness                 147 (52.3)          68 (41.0)        27 (65.9)                         5 (71.4)                21 (61.8)                 26 (78.8)             \< 0.001

   Isolated sensory symptoms      25 (8.9)            20 (12.0)        1 (2.4)                           1 (14.3)                0 (0)                     3 (9.1)               0.096

   Vertebrobasilar symptoms       22 (7.9)            11 (6.7)         4 (9.8)                           1 (16.7)                3 (8.6)                   3 (9.1)               0.867

   Lacunar syndrome               105 (37.5)          61 (36.6)        15 (36.6)                         0 (0)                   9 (25.7)                  20 (62.5)             0.007

   Duration (n = 272)                                                                                                                                                            0.087

    \< 10′                        28 (10.0)           22 (13.3)        3 (7.3)                           1 (14.3)                0 (0)                     2 (6.1)               

   10--59′                        105 (37.4)          58 (34.9)        16 (39.0)                         2 (28.6)                20 (58.8)                 9 (27.3)              

   1 h                            148 (52.7)          86 (51.8)        22 (53.7)                         4 (57.1)                14 (41.2)                 22 (66.7)             

   ABCD2, median (IQR)            5.1 (4.0--6.0)                                                                                                                                 

  Etiological subtypes                                                                                                                                                           

   Large artery disease           61 (21.8)           30 (18.1)        16 (39.0)                         2 (28.6)                11 (32.4)                 2 (6.1)               \< 0.001

   Cardioembolism                 58 (20.7)           34 (20.5)        13 (31.7)                         2 (28.6)                7 (20.6)                  2 (6.1)               

   Small vessel disease           57 (20.4)           33 (19.9)        0 (0)                             \(0\)                   \(0\)                     29 (87.9)             

   Undetermined                   99 (35.2)           68 (41.0)        12 (29.3)                         3 (42.9)                16 (47.1)                 0 (0)                 

  DWI volume, mean (SD)           0.33 (0.15--1.90)   --               0.67 (0.28--2.99)                 0.49 (0.04--1.19)       0.27 (0.07--7.17)         0.23 (0.17--0.68)     0.079
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Percentages are shown in parentheses as appropriate.

DWI, diffusion-weighted images; TIA, transient ischaemic attacks; SD, standard deviation; IQR, interquartile range.

###### 

Molecular features differing between positive DWI and negative DWI patients.

Table 3.

  Metabolite                                                            Discovery cohort   Validation cohort                            
  --------------------------------------------------------------------- ------------------ ------------------- ------- -------- ------- -------
  LysoPA(O-20:0)/5alpha-cholestane-3alpha,7alpha,12alpha,23,25-pentol   452.34             5.98                0.011   452.34   6.21    0.001
  Unknown 1                                                             218.01             0.29                0.028   218.01   0.21    0.007
  Unknown 2                                                             220.11             9.13                0.006   220.11   9.13    0.008
  Creatinine                                                            113.06             0.38                0.050   113.06   0.38    0.012
  Threoninyl-Threonine/*N*-acetyl-b-glucosaminylamine/DiHDPA            362.25             11.67               0.009   362.25   11.94   0.012
  Unknown 3                                                             216.07             0.43                0.007   216.08   0.56    0.013
  Unknown 4                                                             154.97             0.14                0.023   154.97   0.28    0.013
  Unknown 5                                                             157.99             0.30                0.039   157.99   0.23    0.017
  Unknown 6                                                             146.07             0.41                0.019   146.07   0.39    0.038

RT, retention time; LysoPA, lysophosphatidic acid.

Potential identities, based on retention time and exact mass are presented. When it is not possible to attribute only one identity, two or three potential identities are shown.

After Student\'s *t*-test between positive DWI and negative DWI patients.

###### 

Molecular features correlating with acute ischemic lesion volume.

Table 4.

  Identification[a](#tf0015){ref-type="table-fn"}   Discovery cohort   Validation cohort                                           
  ------------------------------------------------- ------------------ ------------------- ------- ------ -------- ------- ------- ------
  LysoPC (22:6)                                     567.33             10.72               0.20    0.06   567.33   10.89   0.29    0.00
  Hypoxanthine/threonate                            136.04             0.78                0.20    0.06   136.04   0.78    0.23    0.01
  Unknown 1                                         294.19             9.36                0.18    0.09   294.19   9.41    0.19    0.02
  LysoPC (20:4)[c](#tf0025){ref-type="table-fn"}    543.33             10.68               0.18    0.08   543.33   11.10   0.18    0.03
  Unknown 2                                         760.03             0.34                -0.21   0.05   760.02   0.33    -0.16   0.04
  Isoleucine/leucine/norleucine                     131.09             0.56                0.30    0.00   131.09   0.55    0.16    0.05
  Unknown 3                                         85.09              0.56                0.29    0.01   85.09    0.55    0.16    0.06

RT, retention time; LysoPC, lysophosphatidylcholine.

Potential identities, based on retention time and exact mass are presented. When it is not possible to attribute only one identity, two or three potential identities are shown.

Correlation coefficient with ischemia volume.

Note the difference in RT between the two cohorts. No peak with similar exact mass and isotope distribution was found closer to the first retention time.

###### 

Molecules differing across DWI patterns.

Table 5.

  Identification[a](#tf0030){ref-type="table-fn"}                                                                      Discovery cohort   Confirmation cohort                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------- ------------------ --------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------- ------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LysoPC(16:0)/LysoPE(19:0)                                                                                            495.33             10.77                 0.02   Normal DWI (70)- Isolated cortical lesion (18); **SPOT(18) - Isolated cortical lesion (18)**; Subcortical (19) - Isolated cortical lesion (18)                                                                                                                                                               495.33   10.78   0.00   **Isolated cortical lesion (16) - SPOT (23);** Normal DWI (83) - SPOT (23)
  2-Oxo-4-methylthiobutanoic acid                                                                                      148.02             9.69                  0.04   Normal DWI(70) - Isolated cortical lesion (18); Subcortical - Isolated cortical lesion (18)                                                                                                                                                                                                                  148.01   9.68    0.00   SPOT (23) - Isolated cortical lesion (16); SPOT (23) - Normal DWI (83)
  Creatinine                                                                                                           113.06             0.38                  0.00   Isolated cortical lesion (18) - Multiples territories (4); Normal DWI(70) - Isolated cortical lesion (18); Subcortical (19) - Isolated cortical lesion (18); Normal DWI(70) - Multiples territories (4); Scattered one territory - Multiples territories (4); Subcortical (19) - Multiples territories (4)   113.06   0.38    0.01   Isolated cortical lesion (16) - SPOT (23); Normal DWI (83) - SPOT (23); Subcortical (14) - SPOT (23)
  Pyroglutamic acid/N-Acryloylglycine/Pyrroline hydroxycarboxylic acid/4-Oxoproline[d](#tf0045){ref-type="table-fn"}   129.04             0.65                  0.02   **Isolated cortical lesion (18) -- SPOT (18)**; **Normal DWI (70)- SPOT(18)**; Subcortical (19) -- SPOT (18)                                                                                                                                                                                                 129.04   0.38    0.01   **Isolated cortical lesion (16) - SPOT (23)**; **Normal DWI (83) -- SPOT (23)**
  Unknown1                                                                                                             760.03             0.34                  0.05   **Normal DWI (70)- Isolated cortical lesion (18)**; SPOT (18) - Isolated cortical lesion (18); Subcortical (19) - Isolated cortical lesion (18)                                                                                                                                                              760.02   0.33    0.02   **Normal DWI (83) - Isolated cortical lesion (16)**; Subcortical (14) - Isolated cortical lesion (16); Normal DWI (83) - SPOT (23); Subcortical (14) - SPOT (23)
  Unknown2                                                                                                             825.97             0.35                  0.02   **SPOT(18) - Normal DWI(70)**; Subcortical (19) - Normal DWI (70)                                                                                                                                                                                                                                            825.98   0.33    0.03   SPOT (23) - Isolated cortical lesion (16); **SPOT (23) - Normal DWI (83)**
  Eicosatrienoic acid                                                                                                  306.26             12.17                 0.05   Isolated cortical lesion (18)- Normal DWI(70); Isolated cortical lesion (18) - Subcortical (19); **SPOT(18) - Normal DWI(70)**; SPOT (18) -- Subcortical (19)                                                                                                                                                306.26   12.13   0.03   SPOT (23) - Isolated cortical lesion (16); **SPOT (23) - Normal DWI (83)**

RT, retention time; LysoPC, lysophosphatidylcholine; SPOT, scattered pearls in one arterial territory; DWI, diffusion-weighted images; LysoPE, lysophosphatidylethanolamine.

Potential identities, based on retention time and exact mass are presented. When it is not possible to attribute only one identity, two or three potential identities are shown.

After ANOVA considering different DWI patterns.

Post-hoc analyses using Fisher\'s Least Significant Difference test, indicating significantly different groups separated by semicolon. Identical differences found in both cohorts are marked by a bold font.

Note the difference in RT between the two cohorts. No peak with similar exact mass and isotope distribution was found closer to the first retention time.

[^1]: These authors contributed equally to this work.
